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1. Introduction 
The structure of the lung is truly remarkable. It is primarily composed of three branched 
tubular networks (the airway, pulmonary artery and vein, bronchial artery and vein) which 
supply blood and air to the site of gas exchange and which maintain nutrient supply to 
supporting tissues. This complex interwoven network is packed into a chest cavity with a 
volume of 6 litres but yet it services a gas-exchange surface area of 130m2, the floor area of a 
comfortably sized Mediterranean holiday villa!  Weibel (1991) tells us that if this surface 
area were arranged as a balloon it would possess a radius of 3m and a volume of 113,000 
litres, more than 18 thousand times the space available in the chest cavity. The process 
which drives this exceptional packaging involves repeated cycles of ordered branching to 
create a fractal network of tubules whose core dimensions decrease at a precise and regular 
rate with each successive branch. This is a high “gain-of–structure” process.  In the airway, 
23 generations of branching form a conducting tubular network with 17 million branches 
and a combined length of more than 7km. This provides convective air flow to 480 million 
alveoli each of which are located along a path length that is no further than 45cm from the 
external atmosphere. The pulmonary vasculature forms along side the airway but 
undergoes an additional five generations of branching to form the capillary network that 
surrounds each alveolus. If you simply assumed that each alveolus (diameter ~200m) was 
serviced by only one blood vessel you would calculate that the alveolar capillary bed alone 
runs to nearly 100 km in length. Realistic attempts at modelling this structure in three 
dimensions suggest that it is, in all probability, between 2 and 6 thousand km long 
(Muhlfield et al., 2010), illustrating the impressive capacity of fractal branching processes to 
package colossal structures into ever smaller spaces.   
The airway and pulmonary vasculature interface with one another at the alveolar blood-
gas barrier where oxygen and carbon dioxide diffuse along partial pressure gradients.  
This extremely thin (0.65m) membrane is composed of cytoplasmic leaflets of type I 
alveolar epithelial cells and capillary endothelial cells held together with a chicken-wire-
like mesh of type IV collagen. Here, a compromise must be met between high surface 
area, thin-ness and tensile strength to ensure that gas exchange proceeds efficiently from 
rest-to-work without rupture of the membrane caused by pressure differences across 
between the alveolar and vascular space. One estimate places the inherent tensile strength 
of this interface at 0.3MPa (West,  2003) which is close to that of pure type IV collagen 
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(1MPa) and similar to that of building  materials such ceramic fibre boards of the type 
often used to line an office ceiling.  
From here, oxygenated blood traverses the branched venous network to the left atrium of 
the heart from where it is circulated around the body. The physiological outcome of this 
interwoven, repeated branching structure is to arrive at a balance between the need for a 
high gas exchange surface area and a minimal energetic cost of breathing, water and heat 
loss. Fractal branching achieves this by dissipating resistance to air and blood movement 
among the exponential rise in tubule number towards the blood-gas barrier, allowing ready 
passage into the recesses of the lung much like water poured into sand. Similarly, this rise in 
surface area ensures that inhaled air is rapidly warmed and hydrated as it passes through 
the upper airways so that ventilating the lung costs little in terms of heat and water loss.  
Thus, for most healthy people, the act of breathing when at rest or asleep is essentially 
subconscious and requires almost imperceptible movement of the chest to maintain 
convective gas exchange over the blood-gas barrier without the need for further anatomical 
specialisation to maintain core body temperature and hydration. Although the mammalian 
lung is clearly a complex organ, this is not to imply that it sits at the pinnacle of evolution 
amongst gas-exchange systems; in fact its structure is derived from imperfect compromise 
between competing selective forces and the interested reader is referred to several articles 
for further insight (Sander et al., 2011; West et al., 2007; Perry et al., 2001; Weibel et al., 1998; 
Weibel, 1984).  
To generate this branched, fractal network a molecular system must be in place to 
programme the duration, bifurcation, orientation and damped repetition of the branching 
cycle.  This chapter reviews the process which controls vascular growth in the lung and, in 
particular, how its regulation is co-ordinated with the fractal branching pattern of the 
airways. 
2. The pattern of vascular development in the lung  
Weibel and Gomez (1962) were among the first to document the fractal branching pattern of 
the airways noting that the decrease in airway diameter for each new branch declined by a 
constant factor (0.85 as re-analysed by Maury et al., 2009). The physiological outcome is to 
dissipate resistance to air flow which, according to Poiseuille’s Law, decreases in proportion 
to the 4th power of tubule diameter. Notably, the rate of decline is slightly shallower than 
the predicted “optimal” rate (0.79) suggesting that there is an excess of dead space within 
the airways. Thus, an evolutionary compromise exists between lung volume and branching  
which accommodates dynamic change in airway diameter caused by exercise, inflammation 
or disease (Maury et al., 2009).  
The pulmonary vasculature closely follows the course of the conducting airways, sharing 
the same rate of branching and decline in diameter up to the 15th generation.   Beyond this, 
vascular branching diverges at a greater rate proceeding through 28 generations to create 
the microvasculature surrounding each alveolus (Weibel, 1991). As with the airways, the net 
outcome is to dissipate resistance to blood flow and achieve a compact, high volume, 
delivery system capable of sustaining a rate of oxygen diffusion over the blood-gas barrier 
of 158mlO2/min/mmHg (Weibel et al., 1993). The way in which this pattern of branching is 
co-ordinated with the growth of the airways is a question of central importance for 
understanding how gas exchange occurs between the blind ended airway network and the 
perfused circuitry of the pulmonary vasculature.     
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Fetal lung development passes through five distinct stages which (in humans) proceed as:  I) 
embryonic (26 days-6 weeks), II) pseudoglandular (6-16 weeks), III) canalicular (16-24 
weeks), IV) saccular (24-36 weeks) and V) alveolar (36 weeks - ~6 years of postnatal life). 
The canalicular stage is the first point at which the vasculature begins to form a functional 
interface with the airway epithelium, however, there is clear evidence that the fate of these 
two structures is intimately linked from the earliest stages of development.  During the 
embryonic stage, the lung develops as a protrusion of foregut endoderm into the 
surrounding mesoderm tissue then bifurcates to form the left and right lung anlage. The 
next two rounds of branching establish the primordial lung lobes and, with them, the 
fundamental structure of the pulmonary vasculature.  
Three models have been proposed to explain how the vasculature develops in the lung. The 
Vasculogenesis Model (Hall et al., 2000) proposes that the pulmonary arteries arise by 
continuous expansion of endothelial cell precursors (angioblasts) that fuse to form blood 
filled hematopoietic lakes in the mesenchyme around each airway bud. Fusion of these lakes 
generates a primitive vasculature which matures as the airway grows forward. This model 
has the advantage of simplicity as it requires only vasculogenic and fusion signals to co-
ordinate its formation with the airway, however, it does not readily explain how ordered 
vascular patterns might form around each airway branch nor how these primitive vessels 
form junctions with existing major blood vessels. De Mello et al. (2000) proposed the Central 
Angiogenesis-Distal Vasculogenesis Model which suggests that the major trunks of the 
pulmonary artery and vein elongate through the mesenchyme surrounding the right and 
left lung lobes in response to an angiogenic cue generated behind each branch tip (central 
angiogenesis). These subsequently fuse with hematopoietic lakes around each branch tip 
(distal vasculogenesis) to form the basis of the pulmonary vasculature. In this model, three 
vascular growth cues are necessary: one to induce angiogenic growth of the major vessels 
along side the developing bud, the second to induce vasculogenesis around the tip of each 
airway branch and the third to fuse these structures together.  
A problem with both of these models is that they fail to adequately explain the presence of 
red blood cells that appear in the vascular structures around each airway branch (Figure 1).  
Parera et al. (2005) examined this issue using transgenic mice bearing a vascular reporter 
gene (lacZ driven by the Tie2 angiopoietin receptor promoter; Tie2-LacZ). They found 
evidence of a continuous, perfused vascular network consisting of Tie2, PECAM-1 and Fli-1 
positive endothelial cells in the mesenchyme tissue that surrounds the left and right airway 
branches. This network is present from the earliest stages of embryonic lung development 
and is derived from the heart vasculature making it inter-connected with other more distant 
structures such as liver and yolk sac. In their Distal Angiogenesis model, they argue that a 
functional vasculature extends from the heart to the distal tip region of each lung branch 
and that vascular growth occurs by endothelial sprouting from perfused blood vessels 
towards an angiogenic cue which is generated from the airway tip (the angiogenic zone; 
Figure 1B). Endothelial sprouts fuse with each other behind the airway bud tip so 
generating a perfused vascular network which surrounds each airway bud.  Importantly, 
this occurs in three dimensions so that the angiogenic process is sustained in parallel with 
airway bud branching (Figure 1C). The growth of the vasculature therefore follows 
angiogenic cues generated by the airway which ensure that the timing and orientation of 
branching events is co-ordinated between these two structures at least up to the 15th 
generation of airway branching.   
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Fig. 1. Vascular growth proceeds by distal angiogenesis in the fetal lung.  A. Tie2 
expression (blue) in E14 fetal Tie2-LacZ mouse heart and lung.  B. Detail showing Tie2 
expression surrounding airway branches. Bright field image below shows airway 
organisation with blood-containing vessels (red hue) in the mesenchyme between each 
airway branch. Simplified schematic at right indicates angiogenic zone (*) at tip of airway 
with perfused vessels (3) orthogonal to the axis of the primary (1) and secondary vascular 
branch (2).  C. Detail of vasculature around airway bud tip.  Left panel: perfused vessels 
(red hue) can be seen in mesenchyme surrounding airway but are absent from angiogenic 
zone ahead of each bud tip (*). Middle panel: Tie2 positive  staining marks primary (1), 
secondary (2) and tertiary (3) vascular branches around single buds. Right panel: 
Simplified schematic showing parallel branching of airway and vasculature through 3 
branch generations (i-iii, airway; 1-3, vasculature).  Abbreviations: Atr, atrium; Bd, airway 
bud; Aw, airway; Dao, dorsal aorta; Mes, mesenchyme;  PPv, perfused pulmonary 
vasculature; RL, LL, right and left lung lobes;  RPA, LPA, right and left pulmonary 
arteries; RPV, right pulmonary vein. V, ventricle 
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3. Airway and vascular growth are inter-dependent processes 
Airway outgrowth is induced by secretion of fibroblast growth factor-10 (FGF-10) from 
discrete regions of the mesenchyme ahead of each new airway branch. As this signal 
encounters the airway epithelium it activates the tyrosine kinase fibroblast growth factor 
receptor-2b (FGFR2b) which stimulates airway tube elongation towards the FGF-10 signal 
(Bellusci et al., 1997). Regulated antagonism of FGF-10 expression and FGFR2b activity 
determines the duration of the growth stimulus and so regulates the length of each airway 
tube and entry into branching.  A seminal study by Metzger et al. (2008) identified three 
different types of branching event that generate the three dimensional structure of the 
conducting airway: i) Domain branching, which establishes the overall shape of each lobe, 
ii) Planar bifurcation, which proceeds on the same plane to form branches towards the 
edge of each lobe and iii) Orthogonal bifurcation where branching occurs 90o to the plane 
of growth. These branching events are governed by four pattern generating events: 
domain specification (the dimensions of each successive branch generation), branch 
periodicity generation (rate and number of branching events), bifurcation (spatial 
separation of branching events) and rotation (angle of branching events relative to the 
axis of the preceding generations). Precise timing of these events in relation to one 
another underpins the fractal pattern of tubular branching observed by Weibel & Gomez 
(1962) for the airway and suggests that airway outgrowth and vascular development are 
co-ordinated through three types of branching event that is controlled by four pattern 
generators; but is the growth of these tubular networks inter-dependent and , if so, which 
regulates which? 
3.1 Linking airway and vascular growth cues 
Pattern generation in the airways is determined, in the first instance, by factors which 
control FGF-10 expression and FGFR2b activity.  FGFR2b signaling in the airway 
epithelium is antagonised by Sprouty2 (Spry2) whose genomic expression and activity is 
induced in response to the FGF-10 signal. Once active, Spry2 suppresses the growth 
response to FGF-10 by blocking the formation of the protein complex which mediates 
guanine nucleotide signaling to the extracellular regulated kinase 1&2 (ERK1/2) pathway. 
The magnitude of this response is governed by the local concentration of FGF-10 around 
the airway bud and so determines the pattern of growth along the airway tube (Scott et 
al., 2010;  Ramasamy et al., 2007; Tefft et al., 2002).  Other ERK1/2 repressors also 
participate in this process to mediate close control over airway bud growth responses  
(eg MKP-3, Spred-1).  Spry2 is therefore poised to regulate the form and magnitude  
of downstream signalling in response to FGF-10 and this includes influence over the 
activity of transcription factors which control vasculogenic signaling (discussed further in 
Section 4.3).   
The duration of FGF-10 expression in the mesenchyme is determined by sonic  
hedgehog (Shh) whose expression is induced in airway epithelial cells in response to the 
FGF-10 signal. Secretion of Shh into the surrounding mesenchyme represses  
FGF-10 expression, forcing lateral movement of this growth inducing cue ahead of regions 
of low Shh expression. This repression of FGF-10 is locally confined by the transcription 
factor sine oculis-1 (Six1) and its co-activator, eyes absent-1 (Eya1), which block the 
expression of the Shh receptor, patched-1 (Ptc1) in the mesenchyme surrounding the 
airways (El-Hashash et al., 2011a,b). Thus, Six1/Eya1 and Shh form the basis of a 
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regulated feedback loop which determines the spatial expression of FGF-10 in the 
mesenchyme.  
Shh also plays a critical role in patterning the formation of other lung structures such as 
smooth muscle and connective tissue which develop around the airway tube as it matures 
(Weaver et al., 2003). It has therefore attracted much attention as a potential link between 
angiogenic and airway growth. Shh is known to regulate the expression of two families of 
angiogenic factors, the vascular endothelial growth factor-A isoforms 120, 164 and 188 
(VEGF-A120, 164, 188) and the vessel maturation factors angiopoietin 1 and 2 (Ang1 and 2). 
VEGF-A is critical for fetal vascular development and knockout of its splice variant forms 
or its cognate receptors, VEGFR1 (Fms-related tyrosine kinase 1 (Flt1)) and VEGFR2 
(synonyms: mouse: Fetal liver kinase-1 (Flk-1); human: Kinase insert Domain Receptor 
(KDR)), causes embryonic lethality before lung development occurs (eg Carmeliet et al., 
1996; Shalaby et al; 1995; Fong et al., 1995). In the pseudoglandular-stage murine lung, 
VEGF-A120 and VEGF-A164 isoforms are expressed in both epithelial and mesenchymal 
tissue and are necessary for endothelial differentiation and angiogenesis towards the 
distal tip of the airway (Del Moral et al., 2006; Greenberg et al., 2002). As tubular 
branching progresses, this angiogenic cue becomes increasingly restricted to the distal 
lung epithelium where it ultimately establishes the vascular side of the blood-gas barrier 
throughout the canalicular to alveolar stages of development (Healy et al., 2000).  
This developmental restriction of VEGF-A164 expression is linked to its association with 
matrix components in the region of the growing bud tip and could be important for 
delineating different types of vascular growth response by altering the 
autophosphorylation pattern of VEGFR2. For example, matrix-associated VEGF-A induces 
distinct phosphorylation of the VEGFR2 tyrosine kinase domain which induces prolonged 
receptor activation, clustering and association with 1 integrin leading to increased 
vascular sprouting (Chen et al., 2010; Gerhardt et al., 2003). It is interesting to speculate 
that this might drive the increased rate of vascular branching that occurs beyond the 15th 
branch generation to create the alveolar microvasculature. Soluble VEGF-A, on the other 
hand, stimulates VEGFR2 association with neurolipin-1 and also receptor internalisation 
which is necessary for vascular maintenance, maturation of the airway epithelium and 
alveologenesis during the later stages of lung growth (Chen et al., 2010; Voelkel et al., 
2006). In fetal lung explants, culture in the presence of soluble VEGF-A164 induces 
vascular growth and endothelial cell differentiation in mesenchyme, whereas inhibition of 
endogenous VEGF-A164 signaling abolishes these effects almost entirely (Zhao et al.,  
2005; Groenman et al., 2007). Notably, these effects are not solely confined to the 
vasculature but also alter airway morphogenesis. For example, soluble VEGF-A164 
augments the rate of tubule branching, however, inhibition of vascular signaling by either 
VEGFR2 knockdown or blockade leads to fewer branches and extensive dilation of 
remaining terminal airway buds (Del Moral et al., 2006; Groenman et al., 2007).  
Thus, VEGF-A signaling is necessary to maintain an appropriate rate of airway  
tubule elongation and branching but it is not an absolute requirement for airway growth 
as such.  
So what of the role of Shh in this process?  Van Tuyl et al (2007) demonstrated that 
knockout of Shh specifically repressed expression of Ang1, but not VEGF-A164 nor 
VEGFR2 and that this suppressed both airway and vascular morphogenesis. Treatment of 
fetal lung explants with pro-angiogenic factors such as FGF-2 or Ang1 reinstated vascular 
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growth and this was associated with a partial recovery of tubular branching suggesting 
that angiogenesis is necessary for airway growth to proceed. A later study showed FGF-9, 
not FGF-2, to be the physiological ligand which underpins this effect and reported 
positive synergistic FGF-9/Shh regulation of VEGF-A164 expression which controlled the 
distribution of endothelial cell proliferation in the mesenchyme surrounding the 
developing airway bud (White et al., 2007). Subsequent vessel maturation is also Shh/Ptc 
dependent as knockout of either Six1/Eya1 leads to defective smooth muscle actin 
expression and vessel wall assembly through sustained Shh signaling to the Ptc receptor 
(El Hayashi et al., 2011a,b). Thus, VEGF-A signaling is critical for co-ordinated vascular 
and airway development and Shh appears to regulate events associated with vessel 
maturation as well as endothelial cell proliferation.   
Shh could also influence airway growth indirectly by simply regulating the maturation rate 
of blood vessels. Lazarus et al. (2011) used 3D re-construction coupled with  VEGF-
A/VEGFR2 genetic ablation to explore perfusion-independent roles of blood vessel 
formation in airway branching in vivo. They demonstrated that the physical absence of 
blood vessels, rather than the inhibition of VEGF signalling per se, has a major influence on 
airway branching process. They also demonstrated that vessels are required for orthogonal 
bifurcation events but have no effect on the planar branching process, such that blood vessel 
ablation leads to an overall “flat” (i.e. planar) lung morphology.  This was linked to a 
disruption of the pattern of FGF-10 expression and de-regulation of the FGF-10/FGFR2b 
antagonism by Shh and Spry2. Thus, blood vessels appear to control branching patterns 
which specifically govern the 3-dimensional development of the conducting airways and the 
factors which control this process are intrinsic to the epithelium-mesenchyme-endothelium 
interface.  
3.2 Does the heart function influence vascular growth of the lung?  
Explant studies show that vascular growth occurs in the lung whether or not it is attached to 
the heart, however, distal angiogenesis ensures that there is a continuously perfused link 
between heart and lung so changes in heart function might also influence airway and 
vascular growth. This would be consistent with the role that the heart plays in determining 
organ placode placement, including trachea and lung,  along the primitive foregut (Cardoso 
& Lü, 2006) and of the vasculature in controlling orthogonal branching later in lung 
development (Lazarus et al.,2011). We investigated this possibility in intact fetal heart and 
lung explants from Tie2-LacZ mice using periodic stimulation to slow heart rate for 10 
minutes at 30 minute intervals over 6h. Fetal lungs were then allowed to develop without 
stimulation for a further 24h before fixing and staining for the Tie2 vascular marker (Figure 
2).The results show that entrainment of pacemaker activity tends to suppress angiogenesisin 
the heart (seen as a reduced intensity of the blue stain) but increases airway branching 
frequency. Lungs grown without the heart attached, but which still received stimulation, 
showed no such difference in airway and vascular growth. Thus, altering patterns of heart 
contractility seems to disconnect the relationship between vascular growth and airway 
morphogenesis suggesting that changes in perfusion rate of the lung, and/or heart-derived 
growth factors which target airway growth, are important determinants of this relationship. 
This is likely to have important consequences for understanding how maternal stress and 
anti-depressant use influences the development of the pulmonary vasculature during 
pregnancy (Morrison et al., 2002).    
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Fig. 2. Altered cardiac pacemaker activity raises airway branching rate and suppresses 
vascular growth. Heart and lungs from E12 Tie2-LacZ mice were excised with all 
connections intact and were and placed into organ culture as described by Scott et al. 
(2010). Pacing was achieved by stimulating preparations (3Hz; 30V) for 10 minute 
intervals every 30 minutes for 6h after which development was allowed to proceed 
normally for a further 18h.  This produced a sustained suppression of heart rate 
(measured at 22oC) from 78 to 58bpm. Distribution of Tie2-lacZ expression (blue colour) 
as a measure of vascular growth was compared to heart-free lung preparation to which 
the pacing regimen had also been applied.  Results shown are representative of  
3 independent experiments.  
4. Regulation of VEGF-A expression in fetal airway epithelium  
Although Lazarus et al. (2011) show that the physical presence of blood vessels is necessary 
to drive orthogonal branching in the lung, it is clear that VEGF-A expression and secretion 
from the elongating airway tube is the earliest possible point of cross-talk between factors 
which regulate airway and vascular growth (Del Moral et al., 2006; Greenberg et al., 2002). 
VEGF-A gene expression is regulated at multiple levels (transcription factor binding at a 
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1.2kb (mouse, rat) to 2.362kb (human) 5’ promoter region;  mRNA stability through protein 
interaction with its 3’ untranslated region; mRNA translation via IRES sequences in the 5’ 
untranslated region) and is intrinsically sensitive to external factors such as oxygen and 
growth factors (reviewed Pagés & Pouyssegur, 2005).  Low oxygen tensions are a persistent 
feature of the uterine environment, ranging from 0-13mmHg during embryonic 
implantation to ~30mmHg throughout  gestation (reviewed, Land, 2004) and raising oxygen 
tension beyond this range is known to inhibit vascular growth (van Tuyl et al., 2005). Given 
the regulated sensitivity of VEGF-A expression to hypoxia, there is therefore an appealing, if  
teleological, argument to suggest that oxygen availability might direct the growth and 
development of the gas exchange system that ensures its delivery to the mitochondrial 
respiratory chain.  
4.1 Hypoxia inducible factors direct vascular growth in the lung 
Oxygen-sensitive VEGF-A expression is regulated by hypoxia inducible factor (HIF) 
binding to a HIF consensus site (TACGTGGG) located in the 5’ proximal VEGF-A 
promoter. HIFs are heterodimeric transcription factors comprising an oxygen regulated 
subunit and a nuclear translocating  subunit.  In hypoxia, the  subunit is stabilised, 
dimerises with the  subunit and is translocated to the nucleus by association with the 
members of the nuclear importer family, importin 1, 3, 5 or 7 (Depping et al., 2008). All 
three HIF isoforms are expressed in the developing lung.  HIF-1 occurs in the 
branching airway epithelium and its homozygous knockout in mice causes developmental 
failure of the vasculature and death by E10.5 (Kotch et al., 1999).  HIF-2 occurs in the 
epithelium and interstitium and its knockout produces vascular defects during alveolar 
septation (Compernolle et al., 2002). HIF-3 is a truncated isoform that lacks the C-
terminal transactivation domain necessary for interaction with p300/CBP and so is 
thought to act as a competitive repressor of HIF-1 and 2 activity (Bardos & Ashcroft, 
2005). Thus, HIF-1 plays the primary role in controlling vascular signalling during lung 
development, whereas HIF-2 function is predominantly associated with the maturation 
of vascular structures and the generation of the blood-gas barrier (Groenman et al., 2007). 
Although growth factors are well known to regulate VEGF-A expression through other 
transcription factors (eg Sp1, AP2; Pages & Pouyssegur, 2005), it seems that HIF-1 and 
2-dependent regulation of vascular growth and blood vessel maturation is critical for 
generating the type of vascular growth, reported by Lazarus et al. (2011), that is necessary 
for three dimensional lung branching to occur.   
HIF-1 stability is regulated by O2-dependent prolyl hydroxylase proteins (PHD1,2,3) and 
an asparaginyl hydroxylase, factor inhibiting HIF (FIH-1). In normoxia, these enzymes 
utilise oxygen and the Krebs cycle intermediate, 2-oxoglutarate, to  catalyse the 
hydroxylation of proline residues 402 and 564 in the oxygen-dependent degradation domain 
of HIF subunits resulting in ubiquitylation by the von Hippel-Lindau E3 ubiquitin ligase 
(VHL) (e.g. Flashman et al., 2008). FIH-1 catalyzes the hydroxylation of asparagine 803 and 
blocks the interaction of the HIF transactivation domain with the CBP/p300 histone 
acetyltransferase. In hypoxia, the loss of oxygen and a decline in Krebs cycle activity results 
in PHD substrate limitation, ODD dehydroxylation, diminished VHL binding and rapid 
HIF stabilisation and transactivation. PHD substrate limitation may also be associated with 
the hypoxia-driven degradation of this enzyme  by a different  E3 ubiquitin ligase, SIAH 
(seven in absentia homolog) (Qi et al., 2008).  PHD proteins critically regulate HIF-1–3 
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stability during lung development, as their inhibition augments HIF target gene expression 
and promotes blood vessel growth and formation of the blood gas barrier (Asikainen et al., 
2005, 2006; Groenman et al., 2007). Of the three PHD isoforms, however, PHD2 appears to 
exert primary regulation of HIF-1 as its knockdown exclusively induces HIF-signaling 
activity and gene expression in normoxia, whereas knockdown of PHD1 and 3 does not 
(Berra et al., 2003).  
Although airway and vascular development is supported better at fetal rather than 
postnatal PO2, and hyperoxia causes severe vascular defects which are associated with 
silencing of the HIF signaling system, it is unlikely that oxygen gradients direct vascular 
growth around the airway tip. In the fetal lung, such gradients would be shallow [~15 
mmHg (20 M)]: difference between the PO2 of the umbilical vein (30 mmHg) and the PO2 
of the amniotic fluid (15mmHg; Land, 2003) and ~10-fold below the Km O2 of PHD enzymes 
(230–250 M; Hirsilä et al., 2003). Moreover, at least in fetal pulmonary vascular smooth 
muscle cells, HIF-1 protein stability is insensitive to oxygen tension suggesting that other 
modes of regulation may be more important in fetal tissues (Resnik et al., 2007). It seems 
more plausible that the low PO2 of the fetal environment may prime the HIF system by 
stabilising the  -subunit and that local regulation is mediated by the growth factors which 
direct airway branching morphogenesis.  
4.2 Co-ordinating HIF activity with airway growth regulators 
In addition to its regulation by PHD proteins, HIF activity is also influenced by kinases 
whose signalling is controlled by tyrosine kinase growth factor receptors (Yee Koh et al., 
2008) and so it is possible that HIF-directed vascular signaling could be induced  from the 
very first interaction between FGF-10 and FGFR2b in the airway bud tip. FGF-10 activates 
FGFR2b by promoting receptor subunit homodimerisation which allows 
autophosphorylation of several tyrosine residues in its intracellular tail region (Figure 3). 
This promotes the binding and tyrosine phosphorylation of the lipid docking protein, suc-1-
associated neurotrophic factor target (FRS2), to the active receptor complex which then 
recruits growth factor receptor-binding protein 2 (GRB2) and its partner, son of sevenless 
(Sos) (Tefft et al., 2002). Simultaneous binding of the protein tyrosine phosphatase, SHP2, to 
FRS2 potentiates GRB2 recruitment further and establishes the overall magnitude of 
receptor signalling activity in response to growth factor binding (Hadari et al., 2001; 
Kouhara et al., 1997). Once this signaling complex is intact, GRB2/Sos catalyses the 
conversion of GDP to GTP on Ras, enabling the Raf serine/threonine kinase to induce MEK-
1 activation of the ERK1/2 signaling pathway.  
FRS2 can also recruit alternative adaptor proteins to induce signaling through other 
pathways. Tyrosine phosphorylation of FRS2ǂ by the active FGF receptor promotes the 
constitutive binding of GRB2-associated binding protein 1 (GAB1) to the C-terminal SH3 
domain of GRB2. This enables tyrosine phosphorylation of GAB1, which is followed by 
recruitment of phosphoinositide-3- kinase (PI3K) by GAB1 resulting in activation of Akt, 
inhibition of the tuberous sclerosis complex proteins 1 & 2 (TSC1/2) and subsequent 
induction of the  mammalian target of rapamycin (mTOR) signaling pathway 
(Eswarakumar et al., 2005).  Thus, the intensity of FGF-10 interaction with its receptor can 
determine the magnitude and duration of signaling through a number of downstream 
pathways that have the potential to regulate HIF-1 activity and VEGF-A expression from 
airway epithelium.   
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Fig. 3. FGF-10 signal transduction to the mTOR and ERK1/2 pathways.  1. FGF-10, secreted 
from mesenchyme ahead of the nascent airway bud, binds to heparin sulphate side chains 
on cell surface proteoglycans and act as a scaffold for FGFR2b homodimerisation.  This 
induces tyrosine autophosphorylation by the active tyrosine kinase domain (TKD) which 
enables FRS2 to bind specific phosphorylated residues and anchor a signal transduction 
cascade to the receptor. 2. ERK1/2 signal transduction cascade. 3. mTOR signal transduction 
cascade. See text for details.  
Scott et al., (2010) investigated this by exposing fetal distal lung epithelial cells (FDLE) from 
pseudoglandular stage rat lungs to FGF-10 concentration gradients at various oxygen 
tensions.  When cultured at alveolar PO2 (13% O2), HIF-1 activity and VEGF-A secretion 
were unresponsive to FGF-10, however, treatment at fetal PO2 (3% O2) produced a dose-
dependent induction of HIF-1activity, without change in its stability, and also raised 
VEGF-A secretion. Both effects were matched by a sustained increase in mTOR activity and 
were suppressed to the endogenous level (i.e. under fetal oxygen tensions) by the mTOR 
inhibitor, rapamycin. Moreover, these effects were accompanied by a dose dependent 
inhibition of ERK1/2 and hypo-phosphorylation of the FGF receptor antagonist, Spry2, 
causing a band-shift to its lighter (35kDa) active form (Figure 4). Thus, it seems that FGF-10 
patterns vascular signalling by favouring mTOR activity over ERK1/2 and that Spry2 may 
partition signaling between these kinase pathways.   
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Fig. 4. FGF-10 induces vascular signaling in fetal distal lung epithelial (FDLE) cells.   
A. FGF-10 induces HIF-1 activity and VEGF-A secretion in hand with altered mTORC-1 
(S6K-phospho Thr389), ERK1/2 (Phospho Thr202/Tyr204) and Spry2 activity (see text for 
details) in FDLE maintained at fetal PO2. Inferred pattern of signaling within the airway 
tubule epithelium is shown below; data from Scott et al., (2010)  B. FGF-10 does not alter 
HIF-1,2 or 3 nuclear abundance in FDLE maintained at fetal PO2.. Positive control, CoCl2 
(100M). 
How mTOR regulates HIF-1 activity remains unclear. Although there is some evidence to 
suggest that this kinase can regulate HIF-1 at the transcriptional level (reviewed Dunlop 
and Tee, 2006), there remains the exciting possibility that it may also directly interact with 
the HIF-1 protein to co-ordinate its function with growth factor signals. mTOR forms two 
distinct multi protein kinase signaling complexes:  mTOR complex 1 (mTORC1: mTOR, 
mammalian LST8/G-protein ǃ-subunit like protein (mLST8/GǃL),  PRAS40, DEPTOR and a 
scaffold protein known as regulatory-associated protein of mTOR (RAPTOR)) and  mTOR 
complex 2 (mTORC2: mTOR, GǃL, mammalian stress-activated protein kinase interacting 
protein 1 (mSIN1) and a scaffold protein known as rapamycin-insensitive companion of 
mTOR (RICTOR)). The arrangement of these complexes partitions mTOR kinase activity 
amongst different substrates such that mTORC1 generally links nutrient and growth factor 
cues to the control of translation, whereas mTORC2 links these cues to cytoskeletal proteins 
which control cell structure (Sarbassov et al., 2004). As mTORC2 is broadly insensitive to 
rapamycin, the observation that this inhibitor blocks FGF-10-evoked HIF-1 activity and 
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VEGF-A secretion suggests that mTORC1 drives early vascular signaling in the fetal lung. 
The scaffold protein RAPTOR binds this complex to its substrates by interacting with 
conserved penta-peptide sequences known as mTOR signaling (TOS) motifs (FDL/IDL and 
FEMDI within S6K1 (Schalm & Blenis, 2002) and 4E-BP1 (Schalm et al., 2003), respectively). 
Mutation of the highly conserved phenylalanine at position 1 of the TOS motif prevents 
mTOR binding and subsequent phosphorylation of its target residues. We identified a 
similarly conserved TOS motif located between amino acids 99 and 104 of HIF-1 (FVMVL) 
which was capable of binding RAPTOR and which was also necessary for growth factor-
sensitive regulation of HIF-1 transcriptional activity (Land and Tee, 2007; Scott et al., 2010).  
Significantly,  this interaction specifically promoted the interaction between the stable HIF-
1/ transcription factor and the CBP/p300 histone acetyltransferase resulting in increased 
efficiency of HIF-regulated gene expression by elevated de-condensation of DNA from its 
histone complex.  
The mTOR pathway plays a critical role in organ development.  In mice, its expression 
arises at E8.5 and its inhibition, by mutation or with rapamycin, results in forebrain 
defects, loss of somites, poor embryonic rotation and lethality by E12.5 (Hentges et al., 
2001). Ontogenic studies of mTOR function in rat fetuses show its activity is high during 
the early stages of development, declining towards term, but rebounds during the early 
neonatal period and corresponds with proportionate changes in translation efficiency 
during gestation and birth (Otulakowski et al, 2009; 2007). In fetal lung in vivo, 
phosphorylation of the mTORC-1 specific substrate, S6 kinase-1 Thr389,  is high in the 
epithelium within the airway bud tip and genomic knockout of its upstream repressor, 
tuberous sclerosis complex-1 (TSC1), leads to gross vascular defects and widespread 
expression of VEGF-A in both airway and mesenchymal tissue (Scott et al., 2010). 
Through its interaction with HIF-1 mTORC1 therefore links FGF-10/FGFR2b activity to 
VEGF-A secretion and vascular growth and provides a mechanism by which the growth 
of the fetal airway epithelium vasculature is linked from the very earliest moment of lung 
development.  
4.3 Linking vascular growth to the FGF-10/FGFR2b/Spry2 airway branching 
periodicity clock 
Although mTORC1 may link the FGF-10 signal to HIF and vascular signaling, it does not 
explain how branching process might occur. Sprouty proteins direct the duration and 
magnitude of growth factor receptor signaling and were originally described as repressors 
of FGF-driven tracheal branching in Drosophila (Hacohen et al., 1998). Here, tracheal 
branching is initiated by the protein product of the Branchless gene (Bnl) whose mammalian 
equivalent is FGF-10. The receptor for the branchless protein is Breathless (Btl), whose 
mammalian orthologue is the FGFR family. The duration of signaling between Bnl and Btl 
(and hence the  length of tubule between each branch) is determined by Sprouty whose 
knockout results in accelerated tracheal branching. Sprouty proteins are therefore 
evolutionarily conserved, inducible inhibitors of FGF-receptor signalling which control the 
branching dimensions of the tracheal airway network.   
In the developing lung, Sprouty proteins play a similar role to define the dimensions of the 
airway tree. Four sprouty isoforms (Spry 1-4) are expressed in mammals but it is Spry2 
which plays the dominant role in the airway branching process, being expressed at the distal 
tip of the epithelial tube bud adjacent to sites of FGF-10 expression in the mesenchyme. 
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Knockdown of Spry2 in fetal lung explants increases epithelial tube branching whereas its 
over-expression in vivo inhibits lung lobation, clefting along the periphery of the lung, 
failure to septate, mesenchymal thickening and an inhibition of epithelial proliferation 
(Mailleux et al., 2001; Tefft, et al., 1999). Later work by Metzger et al. (2008) identified Spry2 
as an important regulator of airway branching whose knockout increased both branch rate 
the restriction of airway diameter so that distal branching patterns occurred proximally in 
the airway. Thus, the FGF-10/FGFR2b/Spry2 feedback loop acts as a timing mechanism 
which controls airway branching periodicity and so defines the fractal characteristics of the 
respiratory tree (Metzger et al., 2008; Warburton, 2008).   
How might Spry2 co-ordinate airway and vascular branching with one another?  Scott et al. 
(2010) showed that a rise in Spry2 activity (appearance of a hypo-phosphorylated 35kDa 
form) accompanies the inhibition of ERK1/2 and activation of mTORC1 that occurs in 
response to FGF-10, therefore, something more than FGFR inhibition must occur to produce 
this partitioning of kinase activity. Spry2 is well documented as an inhibitor of ERK1/2 
signaling following FGF receptor activation (Figure 5). Its structure contains a conserved N-
terminal tyrosine residue at position 55 (Y55) whose phosphorylation by FRS2-activated 
Src kinase (Li et al., 2004) is necessary for interaction with both protein phosphatase 2A 
(PP2A) and the ubiquitin ligase, cCbl (reviewed Guy et al., 2009). No single satisfactory 
explanation exists for what occurs next, however, it is clear that PP2A de-phosphorylates 
two serine residues in a serine rich region of the protein (Ser115 and Ser118) exposing a cryptic 
proline rich tail that can bind SH3 domain proteins and their interacting partners (Lao et al., 
2007). One possibility is that Spry2 therefore acts as an adaptor protein which presents cCbl 
with substrates for ubiquitylation and degradation. This is supported by the observation 
that Grb2, a Spry2 interacting SH3 protein,  can recruit the cCbl E3 ligase and its associated 
ubiquitination machinery into a complex with both FRS2 and FGFR1, so repressing signal 
generation to ERK1/2 (Wong et al., 2002).   
In airway epithelium, FGF-10 similarly increases Spry2 tyrosine phosphorylation 
(presumably at the Y55 residue), promoting its association with the FRS2/Grb2/Raf 
signaling complex and disrupting its formation, either by 1) targeting Grb2-associated 
proteins for proteasomal destruction (Guy et al., 2009; Wong et al., 2002) or 2) inter-calating 
into the FRS2/Grb2 signaling complex thereby disrupting downstream activation of 
ERK1/2 (Tefft et al., 2002). Spry2 activity is repressed by SHP2 which relieves its interaction 
with the Grb2 complex (possibly by dephosphorylating Y55) and whose inhibition results in 
sustained ERK1/2 activity (Hanafusa et al., 2004; Jarvis et al., 2006; Tefft et al., 2002).  Thus, 
much like Shh, Spry2 forms the basis of a feedback loop which controls the duration and 
magnitude of the intracellular signaling response between the FGF receptor and the ERK1/2 
pathway and explains the decline in ERK1/2 activity with increasing FGF-10 concentration 
shown in Figure 4. By implication, ERK1/2 signaling may be more important in the 
functional maturation of the epithelial tube behind the growing bud tip rather than in the 
regulation of airway outgrowth towards the FGF-10 signal.   
Spry2 regulation of mTORC1 and its role in vascular signaling is less clear.  mTORC-1 
assembly and activation is held in check by the activity of two interacting protein partners 
known as Tuberous Sclerosis Complex (TSC) 1 and 2. This acts as a GTPase activating 
protein (GAP) towards the small G-protein known as ras homolog enriched in brain 
(Rheb).   
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Fig. 5. Activation mechanism of Spry2. In its inactive state, Spry2 binds PP2A and is 
phosphorylated at serines 115 and 118. The cryptic C-terminal SH3 binding domain 
(magenta) is hidden within the structure of the protein. FGFR2b autophosphorylation and 
subsequent FRS2 /Grb2 complex assembly activate Spry2 in three steps: 1. Tyrosine 
phosphorylation of c-Src kinase phosphorylates the Y55 residue within the tyrosine kinase 
binding domain of Spry2 (antagonised by the phosphatases, SHP2). This activates protein 
phosphatase 2A (PP2A) enabling it to bind and dephosphorylate serines 115 and 118 within 
the serine rich domain (black). Phosphorylated Y55 also enables binding of the cCbl 
ubiquitin ligase to Spry2.  2. Dephosphorylation of the serine rich domain alters protein 
conformation to expose the SH3 protein binding region. 3. SH3 domain  proteins such as 
Grb2 and, possibly, TSC2, interact with this region, becoming ubiquitylated and 
subsequently targeted for proteasomal clearance.  Clearance of Grb2 and its associated 
proteins prevents ERK1/2 signaling whereas TSC2 clearance prevents GAP activity against 
Rheb, enabling it to bind GTP and activate mTORC1.  
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When bound to GTP, Rheb potently activates mTORC1 kinase activity and this is 
suppressed by TSC1/2 which converts Rheb to its GDP-bound state (Zhang et al., 2003). 
Thus, signaling inputs into TSC1/2 that regulate its GAP activity towards Rheb are critical 
regulators of mTORC1 activity. Spry2 participates in this process in FGF-10-treated FDLE 
cells by forming a complex between TSC2 and cCbl which is associated with an increase in 
Rheb-GTP binding and mTORC1 activation (Figure 5; Scott et al., 2010). Although the 
mechanism that underpins this interaction is unclear, null mutation of the Spry2 Y55 residue 
produced an increase in mTORC-1 dependent HIF-1 activity and VEGF-A secretion that 
was linked to a decline in TSC2 stability and Rheb-GAP activity (Scott et al., 2010).   
Thus, Spry2 appears to direct the partitioning of kinase activity within the FGF-10 gradient 
where pro-vascular mTORC1 activity initiates HIF-1 and VEGF-A secretion from the 
airway epithelium that is close to the FGF-10 source, whereas ERK1/2 activity is specifically 
repressed in this region.  Whether this partitioning is critical for co-ordinating vascular and 
airway branching rate is unclear, however, it may be that Spry2-dependent control over 
mTORC1 governs the duration of proliferative airway and vascular outgrowth around the  
airway tip and that ERK1/2 activity behind this region limits this process by inducing 
tubular maturation towards their functionally developed forms.  There is precedence for this 
from the stem cell literature where activation of ERK1/2 drives terminal differentiation of 
stem cells whereas its inhibition retains cell pleuripotency (Stavridis et al., 2010). 
4.4 An epigenetic role for Spry2 in regulating VEGF-A gene expression? 
The formation of complex, interwoven, branched tubular networks demands tight control over 
the timing and placement of gene expression and this is particularly important for VEGF-A 
where subtle changes in its abundance have major consequences for airway and vascular 
growth. DNA is packaged around complexes of histone proteins (octamers of histones 2A, 2B, 
3 and 4) to form nucleosomes which are further organised into a helical structure to create 
supercoiled chromatin.  Protein tails from each of the histone proteins project outwards from 
the  nucleosome and are modified in different ways (serine phosphorylation, lysine 
acetylation, lysine SUMOylation, arginine methylation,  ubiquitylation) to control DNA 
organisation.  Thus, histone tail modification constitutes an epigenetic code which regulates 
the association of chromatin modifying proteins with DNA and the formation of active 
transcriptional complexes. DNA itself is also subject to modification.  Methylation of cytosine 
residues in CG rich promoter regions (CpG islands) leads to gene repression by inhibiting the 
interaction of transcription complex proteins with the promoter. The three dimensional 
structure of chromatin enables this effect to act over long distances so that distant 
hypermethylated CpG domains (CpG shores) are capable of repressing promoter activity 
located >2kb downstream. The Vegfa gene promoter contains a number of CG rich stretches 
which have been shown to act as binding sites for Sp1 and AP-2 transcription factors 
(reviewed, Pagès & Pouysségur, 2005) but probably do not act as CpG methylation islands 
(Kim et al., 2009). Others have shown that  Vegfa can be targeted by microRNAs (miR) which 
either positively or negatively regulate gene expression by altering histone acetylation and the 
super-ordered structure of the Vegfa coding region (Turunen et al., 2009).  
Given the central importance of temporal and spatial gene regulation patterns to lung 
development, it is reasonable to suppose that Vegfa is subject to some form of epigenetic 
regulation that is sensitive to FGF-10 stimulation. In non-fetal cell lines,  Spry2 distribution 
is characteristically endosomal and migrates to the plasma membrane on tyrosine kinase 
receptor activation by growth factors. In FDLE, however, we have uncovered evidence that 
www.intechopen.com
 Vascular Growth in the Fetal Lung 
 
65 
Spry2 also occurs in the nucleus where chromatin immunoprecipitation (ChIP) assays reveal 
that it interacts with the Vegfa promoter (Figure 6). Although the meaning of this interaction 
is currently unclear, it occurs most strongly in CG-rich regions containing the functional 
binding sites for Sp1 and its competitive repressor, Sp3. The interaction does not appear to 
be dependent upon FGF-10, however, this does not preclude FGF-10-sensitive interactions 
with other protein partners.  Clearly, more work is needed here, however, given that Spry2 
indirectly promotes the interaction between HIF-1 and the CBP/p300 histone 
acetyltransferase (HAT),  it is interesting to speculate that nuclear Spry2 may fine-tune the 
epigenetic regulation of the Vegfa gene by co-ordinating this effect with the  recruitment of 
other transcriptionally active proteins to CG rich domains of the promoter. Given its role as 
a regulator of branching periodicity, could nuclear Spry2 act as the “clock” that regulates the 
timing of gene expression in response to growth factor signals?   
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Fig. 6. Spry2 interacts with CG rich regions of the Vegfa promoter.  A. Location of ChIP assay 
primers spanning the HIF and Sp1/3 binding sites of the Vegfa promoter. Right hand panel 
shows ChIP assay PCR results which reveal a constitutive interaction between Spry2 and  
CG-containing regions of the Vegfa promoter spanning -661 to -124 bases 5’ to the 
transcription initiation site. IgG and Histone 3 (H3) antibodies are negative and positive 
control respectively (representative of four independent assays; S.C. Land, Unpubl. Obs).  B. 
Phosphorylation and acetylation of the H3 tail at Ser10 and Lys 14 promotes DNA 
unwinding from the histone core complex (HC) allowing transcription to proceed.  Spry2 
promotes this by inducing the recruitment of CBP/p300 to HIF-1, via mTORC1.  The role 
of nuclear Spry2 (nSpry2) in this process is speculative but may involve recruitment of other 
transcription factors such as Sp1 or Sp3 to the CG rich region of the Vegfa promoter.  
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5. Conclusion: Towards an integrated model of co-ordinated airway and 
vascular growth in the fetal lung 
The distal angiogenesis model of lung vascular development requires that there is a 
sustained, localized inductive cue which draws vascular growth along the airway branching 
path.  This may be influenced by fetal heart rate which can alter both rate and intensity of 
airway and vascular branching. The model presented in Figure 7 suggests that the earliest 
pro-vascular cue is FGF-10 itself, which induces expression of VEGF-A by amplifying the 
HIF-1 signaling pathway. This occurs by hypo-phosphorylation of Spry2 and cCbl-
dependent inhibition of TSC2 which enables an active mTORC1 complex to interact with the 
HIF-1 N-terminal TOS motif. HIF-promoted VEGF-A expression occurs by enhanced 
CBP/p300 histone acetyltransferase activity binding to HIF-1 which, together with Spry2 
activity elsewhere in the Vegfa promoter, facilitates DNA unwinding and expression of the 
gene. This initial expression of VEGF-A is accompanied by directional cues which sustain 
vascular signaling and blood vessel maturation and also ensure that the patterning of the 
vasculature is confined to appropriate regions of the lung.  The precise nature of these cues 
is unknown, however, it is reasonable to suggest that the FGF-9/Shh interaction performs 
this role as it does for other lung structures (smooth muscle, for example).  Indeed,  this 
interaction could be the basis of the observed need for blood vessels to grow in order to 
sustain the three dimensional growth of the lung.   
Weibel and Gomez’s original observation that the branched patterning of the airway and 
vasculature follows a fractal relationship from one generation to the next implies the 
presence of a “space and time” precision regulator which controls the rate, location and 
orientation of each branch process.  The tight regulation of airway branching patterns in 
lung reported by Metzger et al. (2008) suggests that there is a hierarchy of precision 
regulators which control the “stop”, “bifurcate”, “re-orientate”, “repeat” pattern of 
branching and that there must be some mechanism to unite these events in time along the 
entire branch length.  The exact identity of these processes remains unknown, however, one 
possibility is that calcium waves which regulate smooth muscle peristalsis might serve as 
one periodic orientating cue which co-ordinates these events together on a grand scale 
(Jesudason et al., 2010). Another, is the repressive role that proteins such as Shh and Spry2 
play in determining the spatial patterning and duration of FGF-10 signaling from one 
branch tip to another. At the molecular end of the scale, epigenetic processes determine the 
accessibility of RNA polymerases to DNA coding regions and so it is reasonable to expect 
that the dynamics of histone acetyltransferase and histone deacetylase recruitment to 
specific gene loci, such as Vegfa, determine, when, where and how a developmentally critical 
gene is expressed. This chapter ends on a speculative, but tantalising, note by suggesting 
that Spry2 is a good candidate for this role through its interaction with CG rich regions of 
the Vegfa promoter. 
In the concluding chapter to his book “The Pathway for Oxygen”, Weibel considers whether 
there is an upper limit to the design of the mammalian respiratory system by examining 
lung structure in the smallest mammal with the highest energetic demands, the Etruscan 
shrew.  He reveals a lung of truly extraordinary proportions.  It is ventilated at a rate of 300 
breaths per minute and perfused by a heart that contracts at a rate of 17 beats per second.  
Volume for volume, it has a surface area that is 8-times greater than the human lung and 
which culminates in a blood-gas barrier which is one third the thickness.  Weibel makes the 
point that this can only occur by taking the dimensions of all lung components to their 
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extreme limit and that,  in this organism, the constraints of lung design versus physiological 
demand cannot be pushed further. This suggests that the molecular regulation of airway 
and vascular development is an adaptable process that can be tuned, to a finite limit, to 
generate a lung that can sustain the energetic requirements of the organism.  Understanding 
the molecular regulation of this tuning process in health and disease represents the next 
major goal in lung developmental biology.  
 
TSC1
VEGFVEGF
FGF-10
FGFR2b
mTORC1
HIF-1
A
B
C
A
B
C
cCBLSpry2
Rheb-GTP
TSC2
ERK1/2 Y55
F(99)VMVL
FgO2
FGF-10
secreting 
cells
Mesenchyme 
compartment
Airway 
epithelium
compartment
 
Fig. 7. FGF-10 as a co-ordinator of airway and vascular growth. Right hand panel shows an 
embryonic stage rat lung where perfused vasculature can be seen within the mesenchyme 
surrounding the airway branches and proximal to the airway tip (red hue). Foregut (Fg) is 
shown displaced to left of lung. Signaling in three zones of airway and vascular growth (A-
C) are indicated in the left hand panel.  Zone A: FGF-10 is expressed in the mesenchyme 
ahead of nascent airway buds and diffuses towards the airway epithelium. Zone B: FGF-10 
induces FGFR2b autophosphorylation and signaling to Spry2 whose activation inhibits 
signaling to the ERK1/2 pathway and also induces TSC2 clearance enabling Rheb to bind 
GTP and activate mTORC1.  Zone C: mTORC1 promotes transcriptional activity of hypoxia-
stabilised HIF-1 by interaction with its FVMVL TOS motif.  This augments the expression 
and secretion of VEGF-A into the surrounding mesenchyme so providing the primary 
angiogenic cue which sustains vascular growth along with that of the airway.  Figure 
modified from Scott et al. (2010) with permission.   
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